BR112021020368A2 - Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona - Google Patents
Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-onaInfo
- Publication number
- BR112021020368A2 BR112021020368A2 BR112021020368A BR112021020368A BR112021020368A2 BR 112021020368 A2 BR112021020368 A2 BR 112021020368A2 BR 112021020368 A BR112021020368 A BR 112021020368A BR 112021020368 A BR112021020368 A BR 112021020368A BR 112021020368 A2 BR112021020368 A2 BR 112021020368A2
- Authority
- BR
- Brazil
- Prior art keywords
- chloro
- diazacyclotetradecin
- methene
- pyrazolo
- hexahydro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962832614P | 2019-04-11 | 2019-04-11 | |
| PCT/US2020/027655 WO2020210613A1 (en) | 2019-04-11 | 2020-04-10 | Novel synthetic options towards the manufacture of (6r,10s)-10- {4-[5-chloro-2-(4-chloro-1h-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6h)- pyrimidinyl}- 1-(difluoromethyl)-6-methyl-1,4,7,8,9,10-hexahydro-11,15 -(metheno)pyrazolo [4,3-b] [1,7] diazacyclotetradecin-5(6h)-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021020368A2 true BR112021020368A2 (pt) | 2021-12-07 |
Family
ID=70457148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021020368A BR112021020368A2 (pt) | 2019-04-11 | 2020-04-10 | Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12378246B2 (https=) |
| EP (2) | EP4234555A3 (https=) |
| JP (2) | JP7631218B2 (https=) |
| KR (2) | KR20260047658A (https=) |
| CN (2) | CN114375290B (https=) |
| AR (1) | AR118649A1 (https=) |
| AU (2) | AU2020272973B2 (https=) |
| BR (1) | BR112021020368A2 (https=) |
| CA (1) | CA3132365A1 (https=) |
| EA (1) | EA202192807A1 (https=) |
| ES (1) | ES2969253T3 (https=) |
| IL (1) | IL287102B2 (https=) |
| MX (2) | MX2021012286A (https=) |
| SG (1) | SG11202111132WA (https=) |
| TW (1) | TWI880924B (https=) |
| WO (1) | WO2020210613A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4133064A4 (en) | 2020-04-10 | 2024-07-24 | Codexis, Inc. | Engineered transaminase polypeptides |
| TW202229280A (zh) * | 2020-10-12 | 2022-08-01 | 美商必治妥美雅史谷比公司 | （６ｒ，１０ｓ）－１０－｛４－［５－氯－２－（４－氯－１ｈ－１，２，３－三唑－１－基）苯基］－６－側氧基－１（６ｈ）－嘧啶基｝－１－（二氟甲基）－６－甲基－１，４，７，８，９，１０－六氫－１１，１５－（亞甲橋基）吡唑并［４，３－ｂ］［１，７］二氮雜環十四炔－５（６ｈ）－酮之製備方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012125797A1 (en) | 2011-03-15 | 2012-09-20 | Abbott Laboratories | Nuclear hormone receptor modulators |
| SG10201908467RA (en) | 2014-01-31 | 2019-10-30 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
| NO2721243T3 (https=) | 2014-10-01 | 2018-10-20 | ||
| US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
| CN105294496A (zh) * | 2015-09-28 | 2016-02-03 | 中山大学 | 一种西酞普兰中间体的制备方法 |
| CN110062757B (zh) | 2017-01-18 | 2022-03-04 | 广东东阳光药业有限公司 | 凝血因子XIa抑制剂及其用途 |
| WO2020211781A1 (zh) * | 2019-04-16 | 2020-10-22 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| CN114008047B (zh) * | 2019-07-23 | 2023-03-21 | 南京明德新药研发有限公司 | 作为XIa因子抑制剂的大环衍生物 |
| JP7747337B2 (ja) * | 2020-04-10 | 2025-10-01 | コデクシス， インコーポレイテッド | 速度論的光学分割のためのカルボキシエステラーゼポリペプチド |
-
2020
- 2020-04-10 BR BR112021020368A patent/BR112021020368A2/pt unknown
- 2020-04-10 EP EP23169596.6A patent/EP4234555A3/en active Pending
- 2020-04-10 EP EP20721374.5A patent/EP3953334B1/en active Active
- 2020-04-10 MX MX2021012286A patent/MX2021012286A/es unknown
- 2020-04-10 CN CN202080041935.8A patent/CN114375290B/zh active Active
- 2020-04-10 AU AU2020272973A patent/AU2020272973B2/en active Active
- 2020-04-10 JP JP2021559890A patent/JP7631218B2/ja active Active
- 2020-04-10 IL IL287102A patent/IL287102B2/en unknown
- 2020-04-10 KR KR1020267004972A patent/KR20260047658A/ko active Pending
- 2020-04-10 KR KR1020217036807A patent/KR102929951B1/ko active Active
- 2020-04-10 SG SG11202111132WA patent/SG11202111132WA/en unknown
- 2020-04-10 WO PCT/US2020/027655 patent/WO2020210613A1/en not_active Ceased
- 2020-04-10 TW TW109112263A patent/TWI880924B/zh active
- 2020-04-10 CN CN202411615118.5A patent/CN119775276A/zh active Pending
- 2020-04-10 MX MX2025014306A patent/MX2025014306A/es unknown
- 2020-04-10 EA EA202192807A patent/EA202192807A1/ru unknown
- 2020-04-10 CA CA3132365A patent/CA3132365A1/en active Pending
- 2020-04-10 US US17/602,059 patent/US12378246B2/en active Active
- 2020-04-10 ES ES20721374T patent/ES2969253T3/es active Active
- 2020-04-13 AR ARP200101024A patent/AR118649A1/es unknown
-
2025
- 2025-02-05 JP JP2025017468A patent/JP2025084766A/ja active Pending
- 2025-06-18 US US19/242,506 patent/US20260092066A1/en active Pending
-
2026
- 2026-02-25 AU AU2026201396A patent/AU2026201396A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3953334A1 (en) | 2022-02-16 |
| TWI880924B (zh) | 2025-04-21 |
| US20220144836A1 (en) | 2022-05-12 |
| IL287102A (en) | 2021-12-01 |
| AR118649A1 (es) | 2021-10-20 |
| KR20220045105A (ko) | 2022-04-12 |
| EP4234555A2 (en) | 2023-08-30 |
| JP2022526659A (ja) | 2022-05-25 |
| TW202104188A (zh) | 2021-02-01 |
| ES2969253T3 (es) | 2024-05-17 |
| IL287102B1 (en) | 2025-08-01 |
| EP3953334B1 (en) | 2023-11-22 |
| CN119775276A (zh) | 2025-04-08 |
| CA3132365A1 (en) | 2020-10-15 |
| WO2020210613A1 (en) | 2020-10-15 |
| AU2020272973B2 (en) | 2025-11-27 |
| IL287102B2 (en) | 2025-12-01 |
| EP4234555A3 (en) | 2024-01-03 |
| KR102929951B1 (ko) | 2026-02-24 |
| SG11202111132WA (en) | 2021-11-29 |
| JP7631218B2 (ja) | 2025-02-18 |
| EA202192807A1 (ru) | 2022-02-24 |
| MX2021012286A (es) | 2022-04-06 |
| MX2025014306A (es) | 2026-01-07 |
| JP2025084766A (ja) | 2025-06-03 |
| AU2020272973A1 (en) | 2021-12-02 |
| CN114375290A (zh) | 2022-04-19 |
| KR20260047658A (ko) | 2026-04-08 |
| US12378246B2 (en) | 2025-08-05 |
| CN114375290B (zh) | 2024-11-29 |
| AU2026201396A1 (en) | 2026-03-19 |
| US20260092066A1 (en) | 2026-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003098A1 (es) | Formas amorfas en estado sólido útiles como inhibidores de kras g12c | |
| CL2011000409A1 (es) | Compuestos derivados de tieno[2,3-d]pirimidina; inhibidores de quinasa mnk1 y mnk2; composicion farmaceutica que los comprende y uso en el tratamiento de enfermedades metabolicas, hematopoyeticos, neurodegenerativas, renales, inflamatorias y cancer. | |
| TN2010000131A1 (en) | Polo-like kinase inhibitors | |
| SG10201908467RA (en) | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors | |
| TN2017000524A1 (en) | New bicyclic derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| NZ700236A (en) | Heteroaryl compounds and uses thereof | |
| MX356401B (es) | Pirazol[1,5-a]piridina sustituida como inhibidores de la cinasa del receptor de tropomiosina (trk). | |
| EA201890820A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
| CL2012002318A1 (es) | Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer. | |
| BR112013001632A2 (pt) | composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto | |
| CA2603830A1 (en) | PYRIDINE [2,3-B] PYRAZINONES | |
| BR112021018501A2 (pt) | Compostos de azolamida ativos em termos pesticidas | |
| GEAP201814273A (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
| BR112021020368A2 (pt) | Opções sintéticas para a fabricação de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}-1-(difluorometil)-6-metil-1,4,7,8,9,10-hexa-hidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona | |
| CO2023005883A2 (es) | Procedimiento para la fabricación de (6r,10s)-10-{4-[5-cloro-2-(4-cloro-1h-1,2,3-triazol-1-il)fenil]-6-oxo-1(6h)-pirimidinil}- 1-(difluorometil)-6-metil-1 4,7,8,9,10-hexahidro-11,15-(meteno)pirazolo[4,3-b][1,7]diazaciclotetradecin-5(6h)-ona | |
| CL2008003472A1 (es) | Compuestos derivados de 5-[3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-ona, proceso para la preparacion de los mismos, compuestos intermediarios, composicion farmaceutica que comprende dicho compuesto; combinacion farmaceutica, y sus usos en el tratamiento de enfermedades inflamatorias. | |
| AU2017319080A1 (en) | Pyrazolo[1,5-a]pyrimidine compound | |
| CR20130594A (es) | Monohidrato de derivados de aza-adamantano | |
| MX2019007462A (es) | Formas cristalinas de un inhibidor de quinasa janus. | |
| WO2020159889A9 (en) | Srebp inhibitors comprising a thiophene central ring | |
| PH12021550456A1 (en) | Crystalline forms of a quinazole compound and its hydrochloride salts | |
| BR112015023078A2 (pt) | inibidores de pirrolopirimindina cdk9 quinase | |
| PE20181895A1 (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer | |
| PH12018502246A1 (en) | Substituted fused pyrimidinone compounds | |
| PH12017501832A1 (en) | Stabilized pharmaceutical composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07D 213/61 , C07D 401/04 , C07D 471/18 Ipc: C07D 213/61 (2006.01), C07D 401/04 (2006.01), C07D |